Harrow to Participate in Two Investor Conferences in November
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harrow (HROW) management will participate in investor conferences in New York on November 17 and London on November 18, 2026.
The Craig-Hallum Alpha Select Conference includes one-on-one investor meetings. The Jefferies Global Healthcare Conference includes meetings and a presentation at 8:00 a.m. GMT (3:00 a.m. ET), with a live webcast and replay available for approximately 90 days.
Details
News Market Reaction – HROW
On Nov 12, the day this news came out, HROW closed 3.64% below the previous close. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November:
Craig-Hallum 17th Annual Alpha Select Conference
- Format: 1x1 investor meetings
- Date: Tuesday, November 17, 2026
- Location: New York, NY
2026 Jefferies Global Healthcare Conference
- Format: Presentation and 1x1 investor meetings
- Date/Time: Wednesday, November 18, 2026 at 8:00 a.m. GMT (3:00 a.m. ET)
- Location: London, UK
The Jefferies presentation will be webcast live and can be accessed on the Events page of the Company’s website. A replay of the webcast will be available for approximately 90 days following the presentation. Investors interested in meeting with management during either of these conferences should contact their representative at the sponsoring firm to request a meeting.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890